Suppr超能文献

一种跨学科的诊断方法指导 C3 肾小球病的治疗。

An Interdisciplinary Diagnostic Approach to Guide Therapy in C3 Glomerulopathy.

机构信息

III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans-Knöll-Institute, Jena, Germany.

出版信息

Front Immunol. 2022 May 27;13:826513. doi: 10.3389/fimmu.2022.826513. eCollection 2022.

Abstract

Since the re-classification of membranoproliferative glomerulonephritis the new disease entity C3 glomerulopathy is diagnosed if C3 deposition is clearly dominant over immunoglobulins in immunohistochemistry or immunofluorescence. Although this new definition is more orientated at the pathophysiology as mediated by activity of the alternative complement pathway C3 glomerulopathy remains a heterogenous group of disorders. Genetic or autoimmune causes are associated in several but not in all patients with this disease. However, prognosis is poorly predictable, and clinicians cannot directly identify patients that might benefit from therapy. Moreover, therapy may range from supportive care alone, unspecific immune suppression, plasma treatment, or plasma exchange to complement inhibition. The current biopsy based diagnostic approaches sometimes combined with complement profiling are not sufficient to guide clinicians neither (i) whether to treat an individual patient, nor (ii) to choose the best therapy. With this perspective, we propose an interdisciplinary diagnostic approach, including detailed analysis of the kidney biopsy for morphological alterations and immunohistochemical staining, for genetic analyses of complement genes, complement activation patterning in plasma, and furthermore for applying novel approaches for convertase typing and complement profiling directly in renal tissue. Such a combined diagnostic approach was used here for a 42-year-old female patient with a novel mutation in the Factor H gene, C3 glomerulopathy and signs of chronic endothelial damage. We present here an approach that might in future help to guide therapy of renal diseases with relevant complement activation, especially since diverse new anti-complement agents are under clinical investigation.

摘要

自膜增生性肾小球肾炎重新分类以来,如果免疫组织化学或免疫荧光检查中 C3 沉积明显超过免疫球蛋白,则诊断为新的疾病实体 C3 肾小球病。尽管这种新的定义更侧重于替代补体途径介导的病理生理学,但 C3 肾小球病仍然是一组异质性疾病。在一些但不是所有患者中,遗传或自身免疫原因与这种疾病相关。然而,预后难以预测,临床医生无法直接识别可能受益于治疗的患者。此外,治疗可能从单纯支持治疗、非特异性免疫抑制、血浆治疗或血浆置换到补体抑制不等。目前基于活检的诊断方法有时结合补体谱分析,既不能指导临床医生(i)是否治疗个别患者,也不能指导临床医生(ii)选择最佳治疗方法。有鉴于此,我们提出了一种跨学科的诊断方法,包括对肾脏活检进行详细的形态学改变和免疫组织化学染色分析,对补体基因进行遗传分析,对血浆中补体激活模式进行分析,以及应用新型方法在肾脏组织中直接进行转化酶分型和补体谱分析。在此,我们采用这种联合诊断方法来诊断一名 42 岁女性患者,该患者存在因子 H 基因的新突变、C3 肾小球病和慢性内皮损伤迹象。我们在这里提出了一种方法,该方法可能有助于指导具有相关补体激活的肾脏疾病的治疗,特别是因为许多新的抗补体药物正在进行临床研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验